G. Moro

发表

Relationship between CA 15-3 serum levels and disease extent in predicting overall survival of breast cancer patients with newly diagnosed metastatic disease.

L. Dogliotti, F. Deltetto, M. Tampellini, 1997, British Journal of Cancer.

Radiotherapy Alone or with Concomitant Daily Low-Dose Carboplatin in Locally Advanced, Unresectable Head and Neck Cancer: Definitive Results of a Phase III Study with a Follow-Up Period of up to Ten Years

R. Orecchia, U. Ricardi, P. Gabriele, 2010, Tumori.

Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide v fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer: an Italian multicentre trial.

R. Demicheli, G. Altavilla, V. Adamo, 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic factors in metastatic breast cancer patients obtaining objective response or disease stabilization after first-line chemotherapy with epirubicin. Evidence for a positive effect of maintenance hormonal therapy on overall survival.

P. Zola, A. Bottini, L. Dogliotti, 1997, Anticancer research.

Radiation-induced emesis: a prospective observational multicenter Italian trial. The Italian Group for Antiemetic Research in Radiotherapy.

A. Favero, M. Tonato, R. Corvò, 1999, International journal of radiation oncology, biology, physics.

How radical prostatectomy procedures have changed over the last 10 years in Italy: a comparative analysis based on more than 1500 patients participating in the MIRROR-SIU/LUNA and the Pros-IT CNR study

G. Muto, E. Castelli, F. Bardari, 2020, World Journal of Urology.

Independent Factors Predict Supranormal CA 15-3 Serum Levels in Advanced Breast Cancer Patients at First Disease Relapse

P. Arese, A. Bottini, L. Dogliotti, 2001, Tumor Biology.

Cisplatin, epirubicin, and lonidamine combination regimen as first-line chemotherapy for metastatic breast cancer: a pilot study

P. Zola, A. Bottini, L. Dogliotti, 1998, Cancer Chemotherapy and Pharmacology.

Beyond D’Amico risk classes for predicting recurrence after external beam radiotherapy for prostate cancer: the Candiolo classifier

G. Girelli, P. Gabriele, B. Jereczek-Fossa, 2016, Radiation oncology.

Patterns of Practice in the Radiation Therapy Management of Rectal Cancer: Survey of the Interregional Group Piedmont, Valle d'Aosta and Liguria of the “Associazione Italiana di Radioterapia Oncologica (AIRO)”

P. Franzone, E. Delmastro, A. Bacigalupo, 2013 .

Patterns of practice in the radiation therapy management of rectal cancer: survey of the Interregional Group Piedmont, Valle d'Aosta and Liguria of the "Associazione Italiana di Radioterapia Oncologica (AIRO)".

P. Franzone, E. Delmastro, A. Bacigalupo, 2013, Tumori.

Time to progression in metastatic breast cancer patients treated with epirubicin is not improved by the addition of either cisplatin or lonidamine: final results of a phase III study with a factorial design.

P. Bruzzi, V. Lorusso, A. Bottini, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lonidamine significantly increases the activity of epirubicin in patients with advanced breast cancer: results from a multicenter prospective randomized trial.

P. Zola, A. Bottini, L. Dogliotti, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Does Concomitant Chemoradiotherapy Influence Cosmetic Outcome in Conservative Treatment of Breast Cancer?

V. Borca, M. Stasi, G. Moro, 1997, Tumori.

Evaluation of the Esthetic Results of Conservative Treatment of Breast Cancer

E. Ciambellotti, G. Moro, G. Moro, 1993, Tumori.